Schorge JO - Search Results

1

Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States.

Melamed A, Hinchcliff EM, Clemmer JT, Bregar AJ, Uppal S, Bostock I, Schorge JO, Del Carmen MG, Rauh-Hain JA. Melamed A, et al. Among authors: schorge jo. Gynecol Oncol. 2016 Nov;143(2):236-240. doi: 10.1016/j.ygyno.2016.09.002. Epub 2016 Sep 6. Gynecol Oncol. 2016. PMID: 27612977

2

The effect of postsurgical therapy on stage III endometrial carcinoma.

Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller AF Jr. Schorge JO, et al. Gynecol Oncol. 1996 Oct;63(1):34-9. doi: 10.1006/gyno.1996.0274. Gynecol Oncol. 1996. PMID: 8898165

3

Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy.

Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF Jr. Schorge JO, et al. Gynecol Oncol. 1997 Jul;66(1):31-5. doi: 10.1006/gyno.1997.4691. Gynecol Oncol. 1997. PMID: 9234917 Clinical Trial.

4

Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum.

Schorge JO, Miller YB, Qi LJ, Muto MG, Welch WR, Berkowitz RS, Mok SC. Schorge JO, et al. Gynecol Oncol. 2000 Mar;76(3):369-72. doi: 10.1006/gyno.1999.5711. Gynecol Oncol. 2000. PMID: 10684712

5

Prospective management of stage IA(1) cervical adenocarcinoma by conization alone to preserve fertility: a preliminary report.

Schorge JO, Lee KR, Sheets EE. Schorge JO, et al. Gynecol Oncol. 2000 Aug;78(2):217-20. doi: 10.1006/gyno.2000.5857. Gynecol Oncol. 2000. PMID: 10926806 Clinical Trial.

6

Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix.

Boruta DM 2nd, Schorge JO, Duska LA, Crum CP, Castrillon DH, Sheets EE. Boruta DM 2nd, et al. Among authors: schorge jo. Gynecol Oncol. 2001 Apr;81(1):82-7. doi: 10.1006/gyno.2000.6118. Gynecol Oncol. 2001. PMID: 11277655

7

Early-stage cervical adenocarcinoma treated by surgical intent: the role of para-aortic lymph node dissection.

Lea JS, Sheets EE, Duska LR, Miller DS, Schorge JO. Lea JS, et al. Among authors: schorge jo. Gynecol Oncol. 2002 Feb;84(2):285-8. doi: 10.1006/gyno.2001.6524. Gynecol Oncol. 2002. PMID: 11812088

8

Endocervical curettage at conization to predict residual cervical adenocarcinoma in situ.

Lea JS, Shin CH, Sheets EE, Coleman RL, Gehrig PA, Duska LR, Miller DS, Schorge JO. Lea JS, et al. Among authors: schorge jo. Gynecol Oncol. 2002 Oct;87(1):129-32. doi: 10.1006/gyno.2002.6791. Gynecol Oncol. 2002. PMID: 12468353

9

Adenosquamous histology predicts poor outcome in low-risk stage IB1 cervical adenocarcinoma.

Lea JS, Coleman RL, Garner EO, Duska LR, Miller DS, Schorge JO. Lea JS, et al. Among authors: schorge jo. Gynecol Oncol. 2003 Dec;91(3):558-62. doi: 10.1016/j.ygyno.2003.08.020. Gynecol Oncol. 2003. PMID: 14675676

10

The role of optimal debulking in advanced stage serous carcinoma of the uterus.

Moller KA, Gehrig PA, Van Le L, Secord AA, Schorge J. Moller KA, et al. Gynecol Oncol. 2004 Jul;94(1):170-4. doi: 10.1016/j.ygyno.2004.03.040. Gynecol Oncol. 2004. PMID: 15262137

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

183 results

Search Page

Filters